Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
Alumis' lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage lupus study. The results put a damper on what has ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Alumis’ TYK2 drug fails in key lupus study biopharmadive.com